Searched for
LUPIN STOCK NEWS
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
Stocks in news: HDFC Bank, ICICI Bank, RIL, Trent, Jio FinancialIndian markets are set for a dynamic start today. Investors will closely watch the Q4 results from banking giants HDFC Bank and ICICI Bank....
Stocks in news: IndiGo, Sammaan Capital, Bharti Airtel, GRSE, CoforgeMarkets experienced a sharp sell-off on Monday's monthly expiry day, with the Nifty closing near 22,331. Key companies like IndiGo, Bharti ...
Lupin shares in focus as USFDA inspection at Somerset facility concludes with no observationsEarlier in January, the company received the Establishment Inspection Report (EIR) from USFDA for its Pithampur Unit-1 manufacturing facili...
Buy Lupin, target price Rs 2300: Prabhudas LilladherLupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 93499.24 Crore) operating in Pharmaceuticals s...
Sell Lupin, target price Rs 990: Motilal OswalLupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 53688.88 Crore) operating in Pharmaceuticals s...
Buy Lupin, target price Rs 1165: ICICI DirectLupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 50629.93 Crore) operating in Pharmaceuticals s...
LUPIN: Short-term sideways to bearishLupin’s daily trend is bullish, however, in the last few trading sessions, it is showing weaknesses. In the last trading session, it closed...
Lupin rises over 3% as Brazil subsidiary acquires 9 brands from Bausch HealthThe acquired brands are well established and recognized among doctors and other members of the medical fraternity in Brazil for their relia...
Lupin gets warning letter from FDA for Tarapur facility, stock falls over 2%“We wish to inform you that the company has received a warning letter from the US FDA for the company’s Tarapur, Maharashtra facility. The ...
Lupin skids as failed USFDA specifications lead to recalls of 2 drugsThe company’s scrip fell to a low of Rs 937.15 as against Rs 951.80 at previous close on the National Stock Exchange.
Lupin shares jump 10% in a sudden move; here's whyThe US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI), the Mumbai-headquartered ...
Lupin Q2 results: Firms posts Rs 2,095 crore loss due to one-off impairmentsDuring the quarter, the company booked a provision of Rs 1879.6 crore towards litigation and settlement related to diabetic drug Glumetza c...
Lupin gains 1% on tentative USFDA nod to generic BrexpiprazoleAt 09:30 hours (IST), Lupin’s shares traded at Rs 957.70 on the National Stock Exchange, up 1.11% from previous close.
Licence to sell cancer drug biggest opportunity for Dr Reddy’s in US market: Nirmal Bang‘On a very conservative basis, the drug can add about $300 million to their sales in FY23-FY24.’
Lupin slumps to 4-year low as USFDA issues warning letter for Goa, Indore plantsThe warning letter was issued on Monday for Pithampur unit II of Indore and its Goa plant.
Lupin stock vaults to 52-week high on generic launch of Novartis' DiovanThe stock has gained 25% in the last one year – and has been one of the best performing stocks among the frontline pharma companies.
- Lupin relentlessly compounding at 17-18%: Angel Broking
It is relentlessly compounding at 17-18%, which is a healthy figure and more importantly there is a talk of some inorganic development in L...
- Japan's Takeda eyes Lupin, Cipla pharma business; shares surge in morning trade
Shares of drug firms Cipla and Lupin surged after news reports surfaced that Takeda Pharmaceutical Co, is in talks to buy either of their p...
- Cipla, Lupin shares surge in morning trade on bourses
Shares of drug firms Cipla and Lupin surged after news reports surfaced that Takeda Pharmaceutical Co, is in talks to buy either of their p...